Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
40%(2 trials)

Phase Distribution

Ph phase_2
3
60%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_2

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

NCT00281632
completedphase_1

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

NCT00158782
completedphase_1

A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans

NCT01051700
completedphase_2

GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma

NCT00244764
completedphase_2

Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

NCT00256880

Clinical Trials (5)

Showing 5 of 5 trials
NCT00281632Phase 2

A Phase II, Open-Label Study Evaluating the Effect Of GW786034 In Subjects With Ovarian Cancer

Completed
NCT00158782Phase 1

Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients

Completed
NCT01051700Phase 1

A Safety Study in Healthy Volunteers to Evaluate Safety, How Fast the Drug is Absorbed, and the Side Effects of the Drug in Humans

Completed
NCT00244764Phase 2

GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma

Completed
NCT00256880Phase 2

Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5